Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Marketed
Current status date:
2026-05-21
Original market date: See footnote 1
2025-10-24
Product name:
YESINTEK I.V.
Description:
VIAL
DIN:
02562111
Product Monograph/Veterinary Labelling:
Date:
2026-05-20
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
BIOCON BIOLOGICS CANADA INC
SUITE 6200
1 First Canadian Place, 100 King Street West
Toronto
Ontario
Canada
M5X 1B8
Class:
Human
Dosage form(s):
Solution
Route(s) of administration:
Intravenous
Number of active ingredient(s):
1
Schedule(s):
SCHEDULE D , PRESCRIPTION
Biosimilar Biologic Drug:
Yes
Anatomical Therapeutic Chemical (ATC): See footnote 4
L04AC05 USTEKINUMAB
Active ingredient group (AIG) number:See footnote5
0152506002
| Active ingredient(s) See footnote8 | Strength |
|---|---|
| USTEKINUMAB | 5 MG / ML |
Risk Management Plans See footnote 7
A Risk Management Plan (RMP) for this product was submitted.